Revelation Biosciences, Inc. congratulated its former chairman of the board and shareholder, George Tidmarsh, MD, PhD, on his appointment. Dr. Tidmarsh has been selected to head the FDA Center for Drug Evaluation and Research (CDER). This is a significant leadership role within the U.S. Food and Drug Administration.
Dr. Tidmarsh had previously retired from Revelation Biosciences' Board of Directors due to a potential conflict of interest with his new role. His new position involves working closely with US governmental agencies as an Adjunct Professor at Stanford University School of Medicine. This appointment places a former company leader in a key regulatory oversight role.
This development is noteworthy for Revelation Biosciences as it highlights the caliber of individuals associated with the company. While Dr. Tidmarsh's new role is independent, his prior experience and understanding of drug development could indirectly benefit the broader biotech industry, including companies like Revelation Biosciences, through informed regulatory leadership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.